Research
Hormonal
GLP-1 receptor agonists (e.g., semaglutide) and GLP-2 analogs (e.g., teduglutide) are FDA-approved interventions that treat obesity and short bowel syndrome by mimicking enteroendocrine cell hormone secretion.
If you have obesity or short bowel syndrome, talk to your doctor about GLP-1 based medications like semaglutide. These are FDA-approved treatments that mimic your gut's natural hormones to help with weight loss or nutrient absorption. They are not lifestyle fixes but medical interventions for specific conditions.
StrongSupportsVERY_HIGH confidence
One formulation of semaglutide, Wegovy, has recently been FDA-approved for treating obesity in adults and children over 12 years of age [140].
Why this rating
The paper cites FDA approval and multiple clinical trials (Phase 2/3) for these specific drugs.
Source
Intestinal Enteroendocrine Cells: Present and Future Druggable Targets
Roger Atanga et al. · International Journal of Molecular Sciences · 2023
DOI 10.3390/ijms24108836
narrative_reviewCited 49×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Enteroendocrine cells (EECs) act as chemosensors that secrete hormones (e.g., GLP-1, PYY, CCK) in response to luminal nutrients, regulating appetite, glucose metabolism, and gut motility.Strong
- Obesity and Type 2 Diabetes are associated with altered secretion patterns of enteroendocrine hormones, specifically decreased GLP-1 and PYY, and increased ghrelin.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →